Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain).
80 and over
Aged
COVID-19
Comorbidity
Complications
Epidemiology
Morbidity
Mortality
SARS-CoV-2
Spain
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
30 06 2022
30 06 2022
Historique:
received:
16
03
2022
accepted:
03
06
2022
entrez:
30
6
2022
pubmed:
1
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Old age is one of the most important risk factors for severe COVID-19. Few studies have analyzed changes in the clinical characteristics and prognosis of COVID-19 among older adults before the availability of vaccines. This work analyzes differences in clinical features and mortality in unvaccinated very old adults during the first and successive COVID-19 waves in Spain. This nationwide, multicenter, retrospective cohort study analyzes unvaccinated patients ≥ 80 years hospitalized for COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry). Patients were classified according to whether they were admitted in the first wave (March 1-June 30, 2020) or successive waves (July 1-December 31, 2020). The endpoint was all-cause in-hospital mortality, expressed as the case fatality rate (CFR). Of the 21,461 patients hospitalized with COVID-19, 5,953 (27.7%) were ≥ 80 years (mean age [IQR]: 85.6 [82.3-89.2] years). Of them, 4,545 (76.3%) were admitted during the first wave and 1,408 (23.7%) during successive waves. Patients hospitalized in successive waves were older, had a greater Charlson Comorbidity Index and dependency, less cough and fever, and met fewer severity criteria at admission (qSOFA index, PO2/FiO2 ratio, inflammatory parameters). Significant differences were observed in treatments used in the first (greater use of antimalarials, lopinavir, and macrolides) and successive waves (greater use of corticosteroids, tocilizumab and remdesivir). In-hospital complications, especially acute respiratory distress syndrome and pneumonia, were less frequent in patients hospitalized in successive waves, except for heart failure. The CFR was significantly higher in the first wave (44.1% vs. 33.3%; -10.8%; p < 0.001) and was higher among patients ≥ 95 years (54.4% vs. 38.5%; -15.9%; p < 0.001). After adjustments to the model, the probability of death was 33% lower in successive waves (OR: 0.67; 95% CI: 0.57-0.79). Mortality declined significantly between the first and successive waves in very old unvaccinated patients hospitalized with COVID-19 in Spain. This decline could be explained by a greater availability of hospital resources and more effective treatments as the pandemic progressed, although other factors such as changes in SARS-CoV-2 virulence cannot be ruled out.
Sections du résumé
BACKGROUND
Old age is one of the most important risk factors for severe COVID-19. Few studies have analyzed changes in the clinical characteristics and prognosis of COVID-19 among older adults before the availability of vaccines. This work analyzes differences in clinical features and mortality in unvaccinated very old adults during the first and successive COVID-19 waves in Spain.
METHODS
This nationwide, multicenter, retrospective cohort study analyzes unvaccinated patients ≥ 80 years hospitalized for COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry). Patients were classified according to whether they were admitted in the first wave (March 1-June 30, 2020) or successive waves (July 1-December 31, 2020). The endpoint was all-cause in-hospital mortality, expressed as the case fatality rate (CFR).
RESULTS
Of the 21,461 patients hospitalized with COVID-19, 5,953 (27.7%) were ≥ 80 years (mean age [IQR]: 85.6 [82.3-89.2] years). Of them, 4,545 (76.3%) were admitted during the first wave and 1,408 (23.7%) during successive waves. Patients hospitalized in successive waves were older, had a greater Charlson Comorbidity Index and dependency, less cough and fever, and met fewer severity criteria at admission (qSOFA index, PO2/FiO2 ratio, inflammatory parameters). Significant differences were observed in treatments used in the first (greater use of antimalarials, lopinavir, and macrolides) and successive waves (greater use of corticosteroids, tocilizumab and remdesivir). In-hospital complications, especially acute respiratory distress syndrome and pneumonia, were less frequent in patients hospitalized in successive waves, except for heart failure. The CFR was significantly higher in the first wave (44.1% vs. 33.3%; -10.8%; p < 0.001) and was higher among patients ≥ 95 years (54.4% vs. 38.5%; -15.9%; p < 0.001). After adjustments to the model, the probability of death was 33% lower in successive waves (OR: 0.67; 95% CI: 0.57-0.79).
CONCLUSIONS
Mortality declined significantly between the first and successive waves in very old unvaccinated patients hospitalized with COVID-19 in Spain. This decline could be explained by a greater availability of hospital resources and more effective treatments as the pandemic progressed, although other factors such as changes in SARS-CoV-2 virulence cannot be ruled out.
Identifiants
pubmed: 35773622
doi: 10.1186/s12877-022-03191-4
pii: 10.1186/s12877-022-03191-4
pmc: PMC9244878
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
546Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Clin Med. 2021 Oct 13;10(20):
pubmed: 34682801
J Clin Virol. 2020 Sep;130:104574
pubmed: 32769026
Int J Infect Dis. 2021 Apr;105:374-376
pubmed: 33684560
J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):e28-e37
pubmed: 33103720
Crit Care Explor. 2021 Feb 22;3(2):e0346
pubmed: 33634266
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
JMIR Public Health Surveill. 2022 Jan 6;8(1):e30006
pubmed: 34797774
Public Health. 2021 Nov;200:56-58
pubmed: 34678551
Eur J Phys Rehabil Med. 2021 Jun;57(3):443-450
pubmed: 33393278
Lancet Respir Med. 2021 May;9(5):e47-e48
pubmed: 33684356
Swiss Med Wkly. 2021 Aug 10;151:w20569
pubmed: 34375985
Int J Environ Res Public Health. 2021 Sep 14;18(18):
pubmed: 34574600
N Engl J Med. 2021 Aug 26;385(9):790-802
pubmed: 34351721
Eur J Phys Rehabil Med. 2021 Apr;57(2):181-188
pubmed: 33599442
Glob Epidemiol. 2022 Dec;4:100071
pubmed: 35018339
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Intensive Care Med. 2021 Aug;47(8):867-886
pubmed: 34251506
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32269086
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Acute Med. 2021;20(2):92-100
pubmed: 34190735
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Rev Clin Esp (Barc). 2022 May;222(5):310-311
pubmed: 35101382
Arch Gerontol Geriatr. 2020 Aug 25;91:104240
pubmed: 32877792
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Geriatr Gerontol Int. 2020 Jul;20(7):704-708
pubmed: 32516861
BMC Infect Dis. 2021 Nov 8;21(1):1144
pubmed: 34749645
Stat Med. 1998 Apr 30;17(8):857-72
pubmed: 9595616
J Clin Med. 2021 Oct 08;10(19):
pubmed: 34640628
PLoS One. 2021 Oct 28;16(10):e0258918
pubmed: 34710120
Eur Respir J. 2022 Jan 6;59(1):
pubmed: 34083403
BMC Geriatr. 2021 Jan 15;21(1):63
pubmed: 33451296
Int J Infect Dis. 2022 Mar;116:51-58
pubmed: 34971824
JAMA Intern Med. 2021 Apr 1;181(4):471-478
pubmed: 33351068
Arch Gerontol Geriatr. 2020 Jul - Aug;89:104058
pubmed: 32339960
J Clin Med. 2020 Jun 04;9(6):
pubmed: 32512688
J Med Virol. 2021 Apr;93(4):1896-1899
pubmed: 33295637
J Am Med Dir Assoc. 2021 Sep;22(9):1845-1852.e1
pubmed: 34364846
PLoS One. 2021 May 11;16(5):e0251340
pubmed: 33974637
PLoS One. 2021 Mar 25;16(3):e0249037
pubmed: 33765088
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
BMJ Open. 2022 Jan 3;12(1):e054069
pubmed: 34980623
Lancet Reg Health Eur. 2021 Dec;11:100243
pubmed: 34751263
BMC Public Health. 2021 Nov 11;21(1):2069
pubmed: 34763690
Clin Microbiol Infect. 2021 Dec;27(12):1826-1837
pubmed: 34048876
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1796-1800
pubmed: 32506122
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1788-1795
pubmed: 32279081
Rev Clin Esp (Barc). 2020 Nov;220(8):480-494
pubmed: 32762922
J Gerontol A Biol Sci Med Sci. 2022 Apr 1;77(4):e138-e147
pubmed: 34626477
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Lancet Reg Health Am. 2022 Feb;6:100107
pubmed: 34746913
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052841